A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines
Clinical trial NCT06353971 · TERMINATED
Trial details
- NCT number
- NCT06353971
- Sponsor
- Jasper Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-18
- Primary completion
- 2025-07-31
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.